Today, 2nd
The board's proposal on reducing the share capital (Item 7)
The general meeting decided on the board of directors' proposal to reduce the company's share capital in accordance with the conditions below:
1. The purpose of the reduction is to allocate to unrestricted equity.
2. The company's share capital shall be reduced by
3. The reduction shall be carried out without withdrawal of shares.
The board's proposal on amendments of the articles of association (Item 8)
The general meeting decided on the board of directors' proposal on amending the articles of association as follows:
Current wording | Proposed wording |
§ 4 Share capital The share capital shall be no less than § 5 Number of shares The number of shares shall be no less than 25,000,000 and no more than 100,000,000. | § 4 Share capital The share capital shall be no less than § 5 Number of shares The number of shares shall be no less than 400,000,000 and no more than 1,600,000,000. |
Approving the board's decision on a rights issue of units (
The general meeting approved the board of directors' proposal on that the company shall, through a rights issue, issue a total of up to 639,612,464 shares with a subscription price of
Through a rights issue, the company shall issue a maximum of 79 951 558 warrants of series TO 1, each entitling the holder to subscribe for one (1) new share. In the event that all warrants of series TO 1 are exercised, the share capital may increase by a maximum of
The board's proposal on reducing the share capital (Item 10)
The general meeting decided on the board of directors' proposal to reduce the company's share capital in accordance with the conditions below:
1. The purpose of the reduction is to allocate to unrestricted equity.
2. The company's share capital shall be reduced by
3. The reduction shall be carried out without withdrawal of shares.
The board's proposal on authorizing the board on deciding on issues (Item 11)
The general meeting resolved to authorize the board to decide on the issuance of a maximum number of shares, convertibles, and/or warrants that entitle to subscription of, or result in the issuance of, a maximum number of shares that falls within the limits of the articles of association, with or without deviation from the shareholders' pre-emption rights. The authorization should be valid until the annual general meeting of 2024, and the board should have the right to decide on the detailed terms and conditions of the issuance on each occasion. To ensure that the company's current shareholders are not disadvantaged relative to the external investors who may subscribe for shares, convertibles, and/or warrants in the company, the board finds it appropriate that an issuance with deviation from the shareholders' pre-emption rights should be carried out at a subscription price assessed by the board as market-based, subject to a market-based issue discount where applicable. In addition to cash payment, payment may also be made with in-kind contributions or through set-off, or otherwise under certain conditions.
THE BOARD
For additional information about
Please contact:
Karin Wehlin, Interim CEO
Phone: +46 703 052 488
E-mail: kw@diagonalbio.com
Kerstin Åkesson Jakobsson
Chair of the Board of Directors
Phone: +46 705 504 540
E-mail: kj@diagonalbio.com
Certified Adviser
E-mail: ca@skmg.se
www.diagonalbio.com
https://news.cision.com/diagonal-bio-ab/r/bulletin-from-the-extraordinary-general-meeting-on-tuesday-2-nd--of-april-in-diagonal-bio-ab,c3954790
https://mb.cision.com/Main/20405/3954790/2705008.pdf
(c) 2024 Cision. All rights reserved., source